Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$494.46 USD
-11.32 (-2.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $494.52 +0.06 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRTX 494.46 -11.32(-2.24%)
Will VRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
Other News for VRTX
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday?
3 Biotech Stocks That Could Have Investors Grinning Soon
Vertex Pharmaceuticals (NASDAQ:VRTX) Slides despite Raising Revenue Guidance
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight